This inventor holds 45 USPTO granted patents and 26 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Targeted Protein Degradation. Top assignees: Arvinas Operations, Inc., Merck Sharp + Dohme Corp., Schering Corporation. Active years: 2004-2026.
Location History:
- Rahway, NJ (US) (2018)
- Flemington, NJ (US) (2004 - 2024)
Company Filing History:
23 out of 66 
10 out of 2,405 
10 out of 1,829 
Years Active: 2004-2026
Areas of Expertise:
Title: Innovations by Michael Berlin
Introduction
Michael Berlin, a prominent inventor based in Flemington, NJ, has made significant contributions to the field of pharmaceuticals and biotechnology. With a remarkable portfolio of 36 patents, he has dedicated his career to developing innovative compounds and methods aimed at targeting specific protein interactions, enabling advancements in therapeutic interventions.
Latest Patents
Michael's latest patents include groundbreaking inventions such as "Compounds and methods for the targeted degradation of bromodomain-containing proteins." This invention focuses on bifunctional compounds acting as modulators of targeted ubiquitination. The compounds contain a ligand that binds to the ubiquitin ligase, and a moiety that binds to a target protein, facilitating its degradation. This innovative approach showcases a broad pharmacological activity that addresses the inhibition of various polypeptides.
Another notable patent is titled "Indazole based compounds and associated methods of use." This invention describes hetero-bifunctional compounds that target leucine-rich repeat kinase 2 (LRRK2). By placing the target protein in proximity to the cereblon E3 ubiquitin ligase, these compounds enhance the degradation and inhibition of the target protein, offering potential treatments or preventative measures for diseases arising from its dysregulation.
Career Highlights
Throughout his career, Michael Berlin has worked with notable companies in the field, including Arvinas Operations, Inc., and Schering Corporation. His work has significantly advanced the understanding and manipulation of protein degradation pathways, making him an influential figure in his industry.
Collaborations
Michael has collaborated with esteemed colleagues, such as Robert G. Aslanian and Kevin D. McCormick. These partnerships have fostered an environment of innovation and creativity, allowing the team to pursue cutting-edge research and development in pharmaceuticals.
Conclusion
Michael Berlin's extensive patent portfolio and collaborations highlight his commitment to innovation in the pharmaceutical field. His work not only demonstrates groundbreaking advancements in targeted protein degradation but also underscores the importance of collaborative efforts in driving meaningful discoveries that can impact therapeutic practices.